Torrent Pharmaceuticals Limited Stock

Equities

TORNTPHARM

INE685A01028

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:54 2024-07-15 am EDT 5-day change 1st Jan Change
2,951 INR +0.06% Intraday chart for Torrent Pharmaceuticals Limited +2.65% +28.04%
Sales 2025 * 121B 1.45B Sales 2026 * 136B 1.63B Capitalization 998B 11.95B
Net income 2025 * 20.32B 243M Net income 2026 * 25.97B 311M EV / Sales 2025 * 8.44 x
Net Debt 2025 * 21.58B 258M Net Debt 2026 * 8.5B 102M EV / Sales 2026 * 7.39 x
P/E ratio 2025 *
48.9 x
P/E ratio 2026 *
38.3 x
Employees 15,718
Yield 2025 *
0.87%
Yield 2026 *
1.01%
Free-Float 28.65%
More Fundamentals * Assessed data
Dynamic Chart
Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids RE
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India RE
Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India MT
Torrent Pharmaceuticals Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialize Its Novel Gastrointestinal Drug in India CI
Jefferies Adjusts Torrent Pharmaceuticals’ Price Target to INR3,070 From INR2,930, Keeps at Buy MT
INDIA STOCKS-Indian shares at record highs, boosted by pharma stocks, Adani Ports RE
Torrent Pharmaceuticals' Consolidated Profit Jumps in Fiscal Q4; EPS Tops Estimates MT
Torrent Pharmaceuticals to Raise Up to INR50 Billion via Qualified Institutional Placement MT
Torrent Pharma Board Approves to Raise INR 50,000 Million CI
Torrent Pharmaceuticals Limited Announces Stepping Down of Jinesh Shah as the Director, Effective from 23 July 2024 CI
Torrent Pharmaceuticals Limited Recommends Final Dividend for the Financial Year Ended 31 March, 2024, Payable on or Around 31 July, 2024 CI
Transcript : Torrent Pharmaceuticals Limited, Q4 2024 Earnings Call, May 24, 2024
Torrent Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Torrent Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports RE
More news

Latest transcript on Torrent Pharmaceuticals Limited

1 day+0.06%
1 week+2.65%
Current month+5.78%
1 month+2.25%
3 months+17.14%
6 months+19.16%
Current year+28.04%
More quotes
1 week
2 878.35
Extreme 2878.35
2 977.40
1 month
2 755.00
Extreme 2755
2 977.40
Current year
2 270.15
Extreme 2270.15
2 977.40
1 year
1 771.35
Extreme 1771.35
2 977.40
3 years
1 242.50
Extreme 1242.5
2 977.40
5 years
726.50
Extreme 726.5
2 977.40
10 years
342.60
Extreme 342.6
2 977.40
More quotes
Managers TitleAgeSince
Director of Finance/CFO - -
Compliance Officer - 22-07-31
Chief Operating Officer 47 19-07-31
Members of the board TitleAgeSince
Director/Board Member 70 82-06-22
Chairman 60 85-12-31
Director/Board Member 57 19-03-06
More insiders
Date Price Change Volume
24-07-15 2,951 +0.06% 2 597
24-07-12 2,950 -0.25% 960
24-07-11 2,957 +0.13% 3,044
24-07-10 2,953 +0.58% 6,234
24-07-09 2,936 +2.12% 1,888

Delayed Quote Bombay S.E., July 15, 2024 at 06:00 am EDT

More quotes
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
2,950 INR
Average target price
2,890 INR
Spread / Average Target
-2.03%
Consensus
  1. Stock Market
  2. Equities
  3. TORNTPHARM Stock